4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening
- PMID: 26614027
- DOI: 10.1016/j.ucl.2015.08.004
4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening
Abstract
A preponderance of clinical evidence supports a significant public health benefit for prostate-specific antigen (PSA)-based screening and early detection of prostate cancer in appropriately counseled and selected men. Population-based screening with PSA decreases prostate cancer mortality; however, because of relatively poor specificity, PSA-based screening may also increase the detection of clinically insignificant cancers that would otherwise never require treatment. Use of newer biomarkers that increase the specificity for prostate cancer detection may aid in risk stratification and the appropriate identification of men for prostate biopsy. The authors review the 4-kallikrein panel and 4K probability score.
Keywords: Biomarker; Detection; Kallikrein panel (4K panel); Kallikrein score (4Kscore); Prostate cancer; Screening.
Copyright © 2016 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
